Wolfe Research analyst Gal Munda initiates coverage on Trade Desk (NASDAQ:TTD) with a Peer Perform rating.
AbbVie Announces Lutikizumab Showed Results In A Phase 2 Trial Of Adults With Moderate To Severe Hidradenitis Suppurativa As Program Advances To Phase 3
Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at
